Saturday 17 October 2026
Export INDV’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
32.45
1.17
−3.48%
Follow INDV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
14.20 | 15.09 | 21.23 | 23.49 |
+8 more quarters Free account |
P/S ratio |
3.67 | 2.93 | 3.62 | 2.55 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 25.76 | |
P/Operating CF |
21.32 | (419.95) | (20.29) | (77.28) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.89 | 3.19 | 3.72 | 2.45 | |
EV/EBITDA |
11.85 | 11.74 | 16.34 | 11.52 | |
EV/Operating CF |
(129.41) | (37.11) | (170.70) | 16.33 | |
EV/FCF |
(45.81) | (21.23) | (48.52) | 24.71 | |
Quick Ratio |
0.59 | 0.59 | 0.49 | 0.74 | |
Current Ratio |
0.84 | 0.86 | 0.71 | 0.96 | |
Net Debt/EBITDA |
1.64 | 2.21 | 1.46 | (2.51) | |
Debt/Assets |
39.50% | 40.60% | 26.56% | 22.74% | |
Debt/Equity |
(2.34) | (3.37) | (3.26) | (1.56) | |
Asset Turnover |
0.99 | 1.00 | 0.98 | 0.82 | |
Operating CF/Net income |
1.88 | (0.10) | (2.15) | (0.93) | |
Capex/Depreciation |
(2.33) | (5.00) | (4.80) | (4.00) | |
Interest Coverage |
79.50 | 19.57 | 13.33 | 3.67 | |
Research and Development Expense of Revenue |
3.50% | 5.05% | 5.88% | 10.51% | |
Selling, General and Administrative Expense of Revenue |
35.57% | 39.12% | 52.66% | 49.36% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.21% | 2.84% | 1.40% | 2.23% | |
Graham Net Nets |
(0.15) | (0.18) | (0.14) | (0.23) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
7.04% | 6.63% | 4.71% | 4.26% | |
Free Cash Flow Yield |
(2.31%) | (5.13%) | (2.12%) | 3.88% | |
Revenue per Share |
2.88 | 2.56 | 2.86 | 2.51 | |
Operating CF per Share |
1.92 | (0.07) | (1.77) | (0.31) | |
Capex per Share |
(0.06) | (0.16) | (0.19) | (0.16) | |
Free Cash Flow per Share |
1.87 | (0.23) | (1.96) | (0.47) | |
Cash per Share |
1.87 | 1.41 | 1.56 | 3.56 | |
Shareholders Equity per Share |
(1.75) | (1.16) | (0.78) | (1.66) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.75) | (1.16) | (0.78) | (1.66) | |
Free Cash Flow |
222.00 | (29.00) | (245.00) | (59.00) | |
Working Capital |
(143.00) | (112.00) | (262.00) | (43.00) | |
Capital Expenditures |
(7.00) | (20.00) | (24.00) | (20.00) | |
Net Current Asset Value |
(716.00) | (674.00) | (648.00) | (701.00) | |
EV/EBIT |
12.33 | 12.41 | 17.59 | 12.73 | |
Capex to Sales |
0.02 | 0.06 | 0.07 | 0.06 | |
Price to Operating Income |
11.63 | 11.38 | 17.12 | 13.28 | |
| Other line items | |||||
Average Receivables |
265.00 | 278.50 | 271.00 | 271.50 | |
Average Payables |
201.00 | 180.50 | 233.00 | 515.00 | |
Average Inventory |
149.50 | 157.50 | 160.00 | 166.50 | |
Average Assets |
1,342.50 | 1,286.00 | 1,258.50 | 1,440.00 | |
Average Common Equity |
(232.50) | (215.00) | (218.00) | (187.00) |
Columns are period end dates · fundamentals updated 2 Oct 2026